VANCOUVER -- The head of a Vancouver-based biotech company says he’s frustrated at the delay in delivering what he calls a potentially "life-saving" COVID-19 treatment. Carl Hansen is the CEO of AbCellera, which discovered an antibody treatment for the virus last year. In partnership with Eli Lilly Canada, the two companies developed the drug bamlanivimab. It was first approved for emergency use by Health Canada in November, shortly after FDA approval in the U.S. Since then, Hansen says nearly half a million people over the border have been treated with the drug, but that’s not the case in Canada.